The effects of pitavastatin on glucose metabolism in patients with type 2 diabetes with hypercholesterolemia

Diabetes Research and Clinical Practice

Volumn 106, Issue 3, 2014, Pages 531-537

  Daido, Hisashi ^a,b   Horikawa, Yukio ^b   Takeda, Jun ^b  

^a Hashima Municipal Hospital   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dyslipidemia; Glucose metabolism; Insulin resistance; Insulin secretion; Statin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; PITAVASTATIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; QUINOLINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BODY MASS; DRUG RESPONSE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RELEASE; INSULIN RESISTANCE; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; QUINOLINES; TREATMENT OUTCOME;

EID: 84920705033     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.09.048     Document Type: Article

References (22)

1. Bardini G., Rotella C.M., Giannini S. Dyslipidemia and diabetes: reciprocal impact of impaired lipid metabolism and Beta-cell dysfunction on micro- and macrovascular complications. Rev Diabet Stud 2012, 9:82-93.
2. Fukushima M., Suzuki H., Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004, 66:S37-S43.
3. Brunham L.R., Kruit J.K., Verchere C.B., Hayden M.R. Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest 2008, 118:403-408.
4. Kruit J.K., Kremer P.H., Dai L., Tang R., Ruddle P., de Haan W., et al. Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia 2010, 53:1110-1119.
5. Schaefer E.J., Santos R.D., Asztalos B.F., Marked H.D.L. deficiency and premature coronary heart disease. Curr Opin Lipidol 2010, 21:289-297.
6. Koseki M., Matsuyama A., Nakatani K., Inagaki M., Nakaoka H., Kawase R., et al. Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J Atheroscler Thromb 2009, 16:292-296.
7. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
8. Heart protection study collaborative group MRC/BHF heart protection study of cholesterol-lowing with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
9. Keech A., Colquhoun D., Best J., Kirby A., Simes R.J., Hunt D., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Diabetes Care 2003, 26:2713-2721.
10. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atrovastatin in type 2 diabetes in collaborative atrovastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
11. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
12. Rajpathak S.N., Kumbhani D.J., Crandall J., Barzilai N., Alderman M., Ridker P.M. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:1924-1929.
13. Sattar N., Preiss D., Murray H.M., Welsh P., Buckley B.M., de Craen A.J., et al. Statins and risk of incident diabetes: a collavorative meta-analysis of randomized statin trials. Lancet 2010, 375:735-741.
14. Freeman D.J., Norrie J., Sattar N., Neely R.D., Cobbe S.M., Ford I., et al. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the west of Scotland coronary prevention study. Circulation 2001, 103:357-362.
15. Carter A.A., Gomes T., Camacho X., Juurlink D.N., Shah B.R., Mamdani M.M. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013, 346:f2610.
16. Waters D.D., Ho J.E., DeMicco D.A., Breazna A., Arsenault B.J., Wun C.C., et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011, 57:1535-1545.
17. Waters D.D., Ho J.E., Boekholdt S.M., DeMicco D.A., Kastelein J.J., Messig M., et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013, 61:148-152.
18. Kostapanos M.S., Milionis H.J., Agouridis A.D., Rizos C.V., Elisaf M.S. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract 2009, 63:1308-1313.
19. Yamakawa T., Takano T., Tanaka S., Kadonosono K., Terauchi Y. Influence of Pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008, 15:269-275.
20. Teramoto T., Shimano H., Yokote K., Urashima M. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb 2009, 16:654-661.
21. Teramoto T., Sasaki J., Ueshima H., Egusa G., Kinoshita M., Shimamoto K., et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007, 14:45-50.
22. Odawara M., Yamazaki T., Kishimoto J., Ito C., Noda M., Terauchi Y., et al. Pitavastatin for the delay or prevention of diabetes development in individuals with impaired glucose tolerance. 61-LB, 73th American Diabetes Association Annual Meeting 2013.